Early clinical data from a Phase I/II study at UMass Chan Medical School point to meaningful, measurable benefits from a central nervous system gene therapy for GM2 gangliosidosis, which encompasses Tay-Sachs and Sandhoff diseases. Scienmag.com reported that using a dual adeno-associated virus (AAV) approach, investigators achieved biochemical correction with a favorable safety profile and signs of slowed disease progression.
What patients experienced
- Feeding outcomes improved relative to historical expectations: across dose-escalating cohorts, half of participants sustained full oral intake for more than 25 months. By contrast, many children with GM2 gangliosidosis typically require intravenous nutrition between 13 and 18 months of age.
- Seizure trajectories shifted in a positive direction, with delayed onset and fewer, less severe events that responded better to anticonvulsants. Together, these changes translated into day-to-day functional gains for children and families.
How the therapy works The disorder is driven by mutations (primarily in HEXA or GM2A) that cripple beta-hexosaminidase A (HexA), allowing toxic GM2 gangliosides to accumulate in neurons and drive rapid neurodegeneration beginning in infancy. To address this root deficit, the trial used two rAAVrh8 vectors to deliver therapeutic DNA directly to the thalamus and spinal cord, hubs that influence widespread neural circuits. AAV was chosen for its neuronal tropism, low immunogenicity, and durable, episomal expression that avoids genome integration.
What the trial showed Nine participants received treatment across four dose levels. Although fully normal enzyme activity was not reached, every participant exhibited increased HexA, with activity rising to roughly twice the lower limit of normal. Longitudinal assays confirmed that the transgenes were expressed and functional in neuronal tissue. Adverse events were minimal, supporting continued development.
What comes next The partial biochemical rescue underscores a need to enhance delivery efficiency. The team plans to consolidate the payload into a single vector, effectively doubling DNA per cell without increasing injection volume—an engineering step intended to boost potency, enable earlier use, and potentially shift outcomes if given before symptoms emerge.
Who made it possible The program reflects collaboration across UMass Chan and partners, including independent clinical assessments from Massachusetts General Hospital and vector development co-led by Miguel Sena-Esteves, PhD. Support from rare disease foundations, including the National Tay-Sachs & Allied Diseases Association, Cure Tay-Sachs Foundation, Matthew Forbes Romer Foundation, and Blu Genes Foundation, helped move the concept from bench to bedside. Institutional infrastructure, including MassBiologics, provided the manufacturing backbone for clinical translation.
Why it matters This study offers a practical template for treating lysosomal storage and other inherited neurodegenerative diseases: precise CNS delivery, documented enzyme restoration, and safety suitable for pediatric use. While optimization remains, these findings mark a concrete step toward altering the natural course of Tay-Sachs, Sandhoff, and related GM2 conditions.
